Cleanzine: your weekly cleaning and hygiene industry newsletter 18th April 2024 Issue no. 1110

Your industry news - first

The original and best - for over 20 years!

We strongly recommend viewing Cleanzine full size in your web browser. Click our masthead above to visit our website version.

Picketts Health to sell Zylast for Orbel hand sanitiser applicator

Innovative BioDefense (IBD), manufacturer of the Zylast line of broad-spectrum, persistent antimicrobial products, announced yesterday an exclusive relationship with Australian-based Picketts Health, to provide a modification of its proprietary lotion and antiseptic sanitiser for use in Picketts Health's patented Orbel hand sanitiser applicator.

IBD has delivered a pilot production batch and is currently fulfilling Picketts' first orders. Picketts Health has committed to the purchase of $1.5 million in product from IBD during the first year, with a projection to increase to $4 million in the second year. The first markets the company plans to target are the United Kingdom, South Africa, Australia and China.

The Orbel was designed to increase hand-hygiene compliance and help prevent the spread of bacteria, viruses and infections. Portable, with single-handed activation of a regulated dose, the Orbel's multi-directional balls evenly facilitate distribution to all parts of the hands for increased protection.

The Zylast line of antimicrobial products is all natural, water-based and triclosan-free. Zylast has shown to kill 99.99% of most disease-causing germs in 15 seconds and is persistent for six hours. Independent studies have shown it to be effective against a broad spectrum of germs that includes 25 bacteria such as E. Coli, S. Pneumoniae, meningitis, drug-resistant Methicillin-Resistant S. aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE), viruses such as Rhinovirus (the common cold), Norovirus (the stomach flu), H1N1, HIV and Herpes, as well as moulds and fungi.

"We are pleased Picketts Health has taken an important step towards solving the issue of compliance with the introduction of the Orbel," states Dr. Colette Cozean, chief executive officer, Innovative BioDefense. "Its choice in bringing Zylast in as the formulary shows its commitment to providing the premier antimicrobial solution." Zylast is protected by trademarks and patents pending in many countries worldwide.

T: 1.888.306.0316
E: [email protected]
W: www.zylast.com

5th December 2013